A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Investigational new drugs 2018 Apr .
Aghajanian Carol, Bell-McGuinn Katherine M, Burris Howard A, Siu Lillian L, Stayner Lee-Ann, Wheler Jennifer J, Hong David S, Kurkjian Carla, Pant Shubham, Santiago-Walker Ademi, Gauvin Jennifer L, Antal Joyce M, Opalinska Joanna B, Morris Shannon R, Infante Jeffrey
- Page last reviewed:Mar 1, 2018
- Page last updated:Jun 20, 2019
- Content source: